All peptides
IGF-1 LR3
Also known as: Long R3 IGF-1
Research / Investigational
IGF-1 LR3 is a modified insulin-like growth factor-1 analog with an extended N-terminal peptide and Arg3 substitution, giving it a longer half-life and reduced binding to IGF-binding proteins.
Buy IGF-1 LR3 on American Peptides
Affiliate link — we may earn a commission at no extra cost to you.
Overview
IGF-1 LR3 is a modified insulin-like growth factor-1 analog with an extended N-terminal peptide and Arg3 substitution, giving it a longer half-life and reduced binding to IGF-binding proteins.
FDA Approval Status
Not approved by the FDA. Investigational or intended for research purposes only.
Mechanism of Action
Activates IGF-1 receptors to drive protein synthesis, satellite cell activation, and glucose uptake.
Current Research
Widely used in preclinical work; no approved human indication.
Research strength: Preliminary
Potential Medical Uses
- Investigational only
Potential Benefits
- Reported muscle-cell hyperplasia in models
- Longer half-life than native IGF-1
Known Side Effects
- Hypoglycemia
- Injection-site reactions
- Theoretical tumor promotion
Contraindications
- Active malignancy
- Pregnancy
Drug Interactions
- Insulin (additive hypoglycemia)
Administration Methods
- Subcutaneous injection (research)
Half-life
~20–30 hours (versus minutes for native IGF-1)
Reconstitution
Bacteriostatic water.
Storage & Handling
Refrigerated reconstituted; frozen long-term.
References & Sources
Frequently Asked Questions
Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.